
July 2021 to June 2022
| Drug Name | Government Contribution Dollars | Prescriptions |
|---|---|---|
| AFLIBERCEPT | $499,462,246 | 419,188 |
| PEMBROLIZUMAB | $441,706,702 | 52,050 |
| NIVOLUMAB | $409,231,391 | 53,097 |
| USTEKINUMAB | $302,410,213 | 42,371 |
| APIXABAN | $280,591,048 | 3,434,929 |
| ADALIMUMAB | $275,502,057 | 307,126 |
| DENOSUMAB | $259,778,511 | 1,034,069 |
| LENALIDOMIDE | $245,744,314 | 44,757 |
| RANIBIZUMAB | $199,413,483 | 172,067 |
| OCRELIZUMAB | $194,443,858 | 11,192 |
| RIVAROXABAN | $168,145,152 | 2,510,783 |
| DUPILUMAB | $158,549,855 | 92,806 |
| Drug Name | Government Contribution Dollars | Prescriptions |
|---|---|---|
| ROSUVASTATIN | $97,604,584 | 15,466,261 |
| ATORVASTATIN | $83,038,451 | 12,049,990 |
| PANTOPRAZOLE | $66,600,386 | 9,859,705 |
| ESOMEPRAZOLE | $84,323,885 | 8,445,569 |
| PERINDOPRIL | $43,703,470 | 7,060,090 |
| ESCITALOPRAM | $23,584,883 | 5,900,980 |
| METFORMIN | $42,500,955 | 5,710,913 |
| SERTRALINE | $23,462,936 | 5,504,065 |
| AMLODIPINE | $27,176,268 | 4,692,253 |
| CEFALEXIN | $21,229,359 | 4,595,765 |
| TELMISARTAN | $26,300,051 | 4,432,093 |
| IRBESARTAN | $26,721,077 | 4,154,110 |
| Contributor | Contribution Dollars |
|---|---|
| Australian Government | $14,773,568,888 |
| Patients | $3,400,678,750 |